Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Basking Biosciences, a US-based pharmaceutical firm linked to Duke University and Ohio State University (OSU), has closed a $5.4m series seed round featuring OSU-backed Rev1 Ventures, Broadview Ventures and Viva BioInnovation, the venture capital arm of drug discovery holding company Viva Biotech. Founded in 2019, Basking Biosciences is working on a drug treatment for acute ischemic stroke, based on inventions from Duke University’s Bruce Sullenger and Ohio State University’s Shahid Nimjee. Its lead candidate is expected to enter the…